Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-12-15 |
Vect-Horus (France) |
€ 1.5 million |
fundraising |
BpiFrance (France) |
Technology - Services - Cardiovascular diseases - Cerebrovascular diseases |
Fundraising |
2014-12-10 |
Genfit (France) |
€ 21 million |
private placement |
|
Metabolic diseases - Liver diseases |
Private placement |
2014-12-09 |
Novacyt (France) |
€3.1 million |
private placement |
Alto Invest (France), new and existing Novacyt investors |
Cancer - Oncology - Infectious diseases - Diagnostic |
Private placement |
2014-12-08 |
Quantum Genomics (France) |
€ 3 million |
fundraising |
|
Cardiovascular diseases |
Fundraising |
2014-12-05 |
Molecular Partners (Switzerland) |
CHF 106.2 million |
IPO |
|
Cancer - Oncology - Ophtalmological diseases |
IPO |
2014-12-03 |
Pledpharma (Sweden) |
75 million SEK (€8.1 million) |
private placement |
|
|
Private placement |
2014-12-03 |
Anergis (Switzerland) |
CHF 14.5 Million (€ 12.1 million) |
series B financing round |
Vinci Capital-Renaissance PME (Switzerland) BioMedInvest (Switzerland) Sunstone Capital ( Denmark) Esperante (Sweden) Initiative Capital Romandie (Switzerland) WJFS (USA) |
Allergic diseases - Immunological diseases |
Series B financing round |
2014-12-03 |
Oramed Pharmaceuticals (Israel) |
$5 million |
private placement |
Guangxi Wuzhou Pharmaceutical Company (China) |
|
Private placement |
2014-12-02 |
Xeltis (Switzerland) |
€27 million |
series B financing round |
Life Sciences Partners (LSP) (The Netherlands), Kurma Partners (France), VI Partners (Switzerland) and current shareholders of Xeltis |
Cardiovascular diseases - Medical devices |
Series B financing round |
2014-12-02 |
AyoxxA Biosystems (Germany) |
€ 11.3 million |
series B financing round |
Wellington Partners Venture Capital (Germany), NRW.BANK (Germany), HTGF - High-Tech-Gründerfonds (Germany), KfW (Germany), b-to-v Partners (Germany), Creathor Venture (Germany), HR Ventures (Germany), private investors from the US and Europe, including Ayoxxa employees and two of Qiagen’s founders, BioMedPartners (Switzerland), Grazia Equity (Germany) |
Technology - Services - Diagnostic |
Series B financing round |
2014-12-02 |
Audentes Therapeutics (USA - CA) |
$42.5 million |
series B financing round |
Sofinnova Ventures (USA - CA) Venrock (USA - CA) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA) |
Rare diseases - Genetic diseases |
Series B financing round |
2014-12-01 |
Medgenics (Israel - USA) |
$24.2 million |
private placement |
|
Genetic diseases - Pediatric diseases - Rare diseases |
Private placement |
2014-11-25 |
Promethera Biosciences (Belgium) |
€25.33 million ($31.4 million) |
series C financing round |
SFPI-FPIM (Belgium) SMS Investments (Luxemburg - Germany) Vesalius Biocapital Partners (Luxemburg) SRIW (Belgium) Boehringer Ingelheim Venture Fund (Germany) Shire (UK - USA) Mitsui Global Investment (Japan) ATMI (USA) SambrInvest (Belgium) Walloon Region (Belgium) Pall-ATMI LifeSciences (USA - MN) Vives-Louvain Technology Transfer Office Fund (Belgium) business angels. |
Rare diseases - Genetic diseases - Metabolic diseases - Liver diseases |
Series C financing round |
2014-11-25 |
Cell Medica (UK) |
£50 Million (€ 31.5 million) |
series B financing round |
Imperial Innovations (UK) Invesco Perpetual (UK) Woodford Investment Management (UK) |
Cancer - Oncology - Infectious diseases |
Series B financing round |
2014-11-25 |
Nanobiotix (France) |
up to $25 million |
private placement |
Capital Ventures International (USA) |
Cancer - Oncology |
Private placement |
2014-11-24 |
Orgenesis SPRL (Belgium) Orgenesis (USA - NY) |
€ 2,015 million |
grant |
Walloon Region (Belgium) |
Metabolic diseases |
Grant |
2014-11-20 |
Modern Biosciences (UK) |
£2.4 million (€3 million) |
grant |
Biomedical Catalyst Fund (UK) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
Grant |
2014-11-20 |
Heptares (UK) |
£1.5 million (€1.8 million) |
grant |
Biomedical Catalyst Fund (UK) |
Metabolic diseases - Rare diseases |
Grant |
2014-11-19 |
Cempra (USA - NC) |
$16 million |
grant |
Biomedical Advanced Research and Development Authority (USA) |
Infectious diseases |
Grant |
2014-11-18 |
Intellia Therapeutics (USA - MA) |
$15 million |
series A financing round |
Atlas Venture (USA - MA) Novartis (Switzerland) |
Technology - Services |
Series A financing round |